• Resveratrol as a SIRT1 Activator: Neuroprotection in N2a Cel

  2026-07-22

  Resveratrol’s precise SIRT1 activation unlocks robust mitochondrial protection and apoptosis inhibition in prion-challenged neuroblastoma models. This article delivers validated workflows, troubleshooting insights, and a translational perspective for leveraging APExBIO’s high-purity Resveratrol in cutting-edge neurodegeneration research.

• (S)-(+)-Dimethindene maleate: Precision M2 Antagonist for Re

  2026-07-22

  (S)-(+)-Dimethindene maleate (SKU B6734) enables selective inhibition of M2 muscarinic receptors for rigorous studies of autonomic, cardiovascular, and respiratory functions. Its defined receptor selectivity and robust workflow compatibility address the need for reproducible antagonism in receptor signaling assays. Use is limited to research applications and should be avoided for long-term solution storage or clinical use.

• CD36-Driven Lipid Metabolism Enables Immune Escape in AML

  2026-07-21

  Guo et al. elucidate how CD36-mediated uptake of oxidized LDL and palmitate in AML cells triggers a non-canonical lipid metabolism program that suppresses T cell function and promotes resistance to hypomethylating agent therapy. These findings highlight novel metabolic vulnerabilities that can be targeted to overcome immune evasion and therapeutic resistance in acute myeloid leukemia.

• Optimizing Cannabinoid Research with Rimonabant (SR141716) S

  2026-07-21

  This article delivers actionable, scenario-driven guidance for biomedical researchers utilizing Rimonabant (SR141716) (SKU B1429) in cell viability, proliferation, and cytotoxicity assays. It emphasizes data-backed protocol optimization, reproducibility, and vendor reliability while integrating current literature and APExBIO’s validated product advantages.

• Cediranib (AZD2171): Optimizing Angiogenesis Inhibitor Workf

  2026-07-20

  Cediranib (AZD2171) sets a new standard for precision in angiogenesis and VEGFR pathway inhibition assays, enabling reproducible and nuanced experimental outcomes. By leveraging advanced in vitro models and actionable protocol enhancements, researchers can dissect tumor signaling with unparalleled clarity and troubleshoot workflow bottlenecks efficiently.

• Optimizing Opioid Receptor Assays with nor-Binaltorphimine d

  2026-07-20

  This article delivers practical, scenario-driven guidance for using nor-Binaltorphimine dihydrochloride (SKU B6269) in opioid receptor signaling research. Drawing on recent literature and real-world assay challenges, it demonstrates how SKU B6269 enables reproducible, selective interrogation of κ-opioid receptor pathways, elevating data quality and experimental confidence.

• EZ Cap EGFP mRNA 5-moUTP: Enhancing mRNA Delivery Workflows

  2026-07-19

  EZ Cap™ EGFP mRNA (5-moUTP) empowers high-fidelity gene expression workflows with robust stability, immune evasion, and strong fluorescent output. Its Cap 1 structure and 5-moUTP modifications enable superior translation efficiency for advanced cell and in vivo imaging assays. This guide details applied protocols, troubleshooting strategies, and practical innovations for maximizing experimental success.

• Olaparib (AZD2281): Precision PARP Inhibition in Cancer Rese

  2026-07-18

  Olaparib (AZD2281) is a highly selective PARP-1/2 inhibitor pivotal for DNA damage response studies and BRCA-associated cancer targeted therapy. Evidence supports its synthetic lethality mechanism in homologous recombination-deficient tumors and its expanding utility in combination strategies for hepatocellular carcinoma and radiosensitization. This dossier details mechanism, benchmarks, and protocol parameters for research use.

• TLR-NF-κB Axis and AIM2 Inflammasome in PRV-Driven Inflammat

  2026-07-17

  This study reveals that pseudorabies virus (PRV) infection activates a network of Toll-like receptors (TLRs) leading to NF-κB signaling and AIM2 inflammasome assembly, resulting in robust pro-inflammatory cytokine production in mice. The findings clarify the molecular mechanisms underlying PRV-induced inflammation, offering new avenues for targeted investigation of NF-κB pathway dynamics in infectious disease models.

• Mechanisms and Toxicity of Dimetridazole Degradation by Hydr

  2026-07-17

  This study offers a quantum chemical analysis of Dimetridazole (1,2-Dimethyl-5-nitroimidazole) and Ornidazole degradation via hydroxyl radicals in water, revealing detailed mechanistic steps, kinetic parameters, and the evolving aquatic toxicity of transformation products. The results provide vital insight for the environmental fate, remediation strategies, and ecotoxicological risk assessment of nitroimidazole antibiotics.

• Necrostatin 2 (Nec-2): Applied Workflows for Necroptosis Inh

  2026-07-16

  Necrostatin 2 (Nec-2) is redefining necroptosis research with exceptional specificity for RIPK2, enabling precise dissection of programmed necrotic cell death in infectious and ischemic models. Explore how practical protocol enhancements and troubleshooting tips maximize its translational value for inflammation, Kupffer cell biology, and ischemic stroke research.

• MK-0812: Precision CCR2 Inhibition in Monocyte Trafficking A

  2026-07-16

  MK-0812 empowers metabolic inflammation studies with nanomolar precision and robust blockade of monocyte recruitment. Its selectivity and proven in vivo efficacy make it indispensable for dissecting CCR2-mediated mechanisms in advanced gut–liver axis models.

• SIRT1/2 Inhibitor IV (cambinol): Precision Tools for Non-His

  2026-07-15

  Explore how SIRT1/2 Inhibitor IV (cambinol) advances research into SIRT1-driven non-histone lactylation and astrocyte polarization after CNS injury. This article delivers deep mechanistic insight and practical protocol guidance for scientists investigating metabolic, epigenetic, and tumorigenic pathways.

• Verapamil HCl: Mechanistic and Strategic Insights for Transl

  2026-07-15

  This article offers a scientific deep-dive into the use of Verapamil HCl, a phenylalkylamine L-type calcium channel blocker, as both a mechanistic probe and a translational enabler in myeloma and arthritis inflammation models. By integrating recent mechanistic findings with actionable guidance, we empower researchers to enhance both experimental rigor and translational impact.

• Berberine Hydrochloride Expands Tuft Cells to Counter Bone L

  2026-07-14

  This study demonstrates that berberine hydrochloride mitigates estrogen deficiency-induced bone loss by expanding intestinal tuft cells through a butyrate-mediated gut-bone axis mechanism. These insights reveal a novel regulatory pathway for postmenopausal osteoporosis, supporting advanced research in osteoimmunology and metabolic modulation.

458 records 11/31 page Previous Next First page 上5页 1112131415 下5页 Last page